Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC-Reference-Cited by-同舟云学术

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC

Published:2017-08-03 Issue:42 Volume:8 Page:72544-72563
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

MacDonagh Lauren¹,Gallagher Michael F.²,Ffrench Brendan²,Gasch Claudia²,Breen Eamon³,Gray Steven G.¹,Nicholson Siobhan⁴,Leonard Niamh⁴,Ryan Ronan⁵,Young Vincent⁵,O’Leary John J.²,Cuffe Sinead¹,Finn Stephen P.¹⁴,O’Byrne Kenneth J.¹⁶,Barr Martin P.¹

Affiliation:

1. Thoracic Oncology Research Group, School of Clinical Medicine, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital & Trinity College, Dublin, Ireland

2. Histopathology Department, Trinity College Dublin, Sir Patrick Dun Laboratories & Central Pathology Laboratory, St. James's Hospital, Pathology Research Laboratory, Coombe Women and Infant's University Hospital, Dublin, Ireland

3. Flow Cytometry Facility, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital & Trinity College, Dublin, Ireland

4. Histopathology Department, St. James's Hospital, Dublin, Ireland

5. Department of Cardiothoracic Surgery, St. James's Hospital, Dublin, Ireland

6. Cancer & Ageing Research Program, Queensland University of Technology, Brisbane, Australia

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baicalin promotes the sensitivity of NSCLC to cisplatin by regulating ferritinophagy and macrophage immunity through the KEAP1-NRF2/HO-1 pathway;European Journal of Medical Research;2024-07-26

2. The role of metal ions in the occurrence, progression, drug resistance, and biological characteristics of gastric cancer;Frontiers in Pharmacology;2024-02-02

3. A cisplatin and disulphiram co-loaded inclusion complex overcomes drug resistance by inhibiting cancer cell stemness in non-small cell lung cancer;Journal of Drug Targeting;2024-01-07

4. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status;Proceedings of the National Academy of Sciences;2023-11-16

5. Regulating POLR3G by MicroRNA-26a-5p as a promising therapeutic target of lung cancer stemness and chemosensitivity;Non-coding RNA Research;2023-09